Trial Outcomes & Findings for Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention (NCT NCT00618436)

NCT ID: NCT00618436

Last Updated: 2014-04-07

Results Overview

This was the number of patients in each group who demonstrated seizure activity during the course of the study

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

52 participants

Primary outcome timeframe

Duration of study, up to 6 months after the injury

Results posted on

2014-04-07

Participant Flow

Participant milestones

Participant milestones
Measure
Levetiracetam
This group will receive treatment with Levetiracetam.
Phenytoin
This group will receive treatment with Phenytoin.
Overall Study
STARTED
34
18
Overall Study
COMPLETED
34
18
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Levetiracetam
n=34 Participants
This group will receive treatment with Levetiracetam.
Phenytoin
n=18 Participants
This group will receive treatment with Phenytoin.
Total
n=52 Participants
Total of all reporting groups
Age, Continuous
44 years
n=99 Participants
35 years
n=107 Participants
42.5 years
n=206 Participants
Sex: Female, Male
Female
8 Participants
n=99 Participants
5 Participants
n=107 Participants
13 Participants
n=206 Participants
Sex: Female, Male
Male
26 Participants
n=99 Participants
13 Participants
n=107 Participants
39 Participants
n=206 Participants
Region of Enrollment
United States
34 participants
n=99 Participants
18 participants
n=107 Participants
52 participants
n=206 Participants

PRIMARY outcome

Timeframe: Duration of study, up to 6 months after the injury

This was the number of patients in each group who demonstrated seizure activity during the course of the study

Outcome measures

Outcome measures
Measure
Levetiracetam
n=34 Participants
This group will receive treatment with Levetiracetam.
Phenytoin
n=18 Participants
This group will receive treatment with Phenytoin.
Seizure Incidence
5 Participants
3 Participants

SECONDARY outcome

Timeframe: at discharge; 3 and 6 months following injury

Population: All patients

This is an 8 point validated scale that measures disability after brain injury. It is assessed through an in person exam or by phone interview at hospital discharge, 3 months and 6 months after injury. The categories are: 1 = dead; 2 = vegetative state; 3 = severe disability, low level; 4 = severe disability, high level; 5 = moderate disability, low level; 6 = moderate disability, high level; 7 = good recovery - low level; 8 = good recovery - high level. Specific questions and activities are assessed to determine into which category the patient falls.

Outcome measures

Outcome measures
Measure
Levetiracetam
n=34 Participants
This group will receive treatment with Levetiracetam.
Phenytoin
n=18 Participants
This group will receive treatment with Phenytoin.
Extended Glasgow Outcome Score
At Discharge
2 units on a scale
Interval 1.0 to 4.0
2 units on a scale
Interval 1.0 to 3.0
Extended Glasgow Outcome Score
At 3 months
3 units on a scale
Interval 1.0 to 7.0
3 units on a scale
Interval 1.0 to 5.0
Extended Glasgow Outcome Score
At 6 months
3 units on a scale
Interval 1.0 to 8.0
3 units on a scale
Interval 1.0 to 7.0

SECONDARY outcome

Timeframe: Discharge; 3 and 6 months following injury

Population: All patients

The Disability rating scale (DRS) is frequently used in the rehabilitation literature as a measure of disability. It is a reliable, easily performed test that assesses 8 items (eye opening, verbalization, motor response, feeding, toileting, grooming, level of functioning, employability), and assigns each a numerical score ranging from 0 - 5 based on the category. The domains these 8 items are felt to assess include: alertness, cognition for self-care, dependence, and psychosocial adaptability. The scoring range is from 0-30, with increasing disability levels assigned to higher numerical values. The total DRS is then dichotomized into favorable (disability = none, mild, partial or moderate disability) and unfavorable (disability = moderately severe, severe, extremely severe, vegetative state, extreme vegetative state, death) outcomes. A DRS score of 0-6 was favorable, with any score greater than 6 categorized as unfavorable.

Outcome measures

Outcome measures
Measure
Levetiracetam
n=34 Participants
This group will receive treatment with Levetiracetam.
Phenytoin
n=18 Participants
This group will receive treatment with Phenytoin.
Disability Rating Scale (DRS)
At Discharge
24 units on a scale
Interval 7.0 to 30.0
23 units on a scale
Interval 7.0 to 30.0
Disability Rating Scale (DRS)
At 3 months
15 units on a scale
Interval 0.0 to 30.0
13 units on a scale
Interval 5.0 to 30.0
Disability Rating Scale (DRS)
At 6 months
17 units on a scale
Interval 0.0 to 30.0
9 units on a scale
Interval 0.0 to 30.0

SECONDARY outcome

Timeframe: discharge; 3 and 6 months following injury

Outcome measures

Outcome data not reported

Adverse Events

Levetiracetam

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Phenytoin

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Lori Shutter

University of Pittsburgh

Phone: 1-412-647-8410

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place